更新于：2024-06-30
Mequitazine
美喹他嗪
更新于：2024-06-30
概要
基本信息
原研机构 |
非在研机构- |
最高研发阶段批准上市 |
最高研发阶段(中国)- |
特殊审评- |
登录后查看首次获批时间轴
结构
分子式C20H22N2S |
InChIKeyHOKDBMAJZXIPGC-UHFFFAOYSA-N |
CAS号29216-28-2 |
关联
51
项与 美喹他嗪 相关的临床试验Assessment of the Impact of Soft Tissue Mobilization on the Scar in Patients After Cesarean Section
Efficacy of Physical Therapy Intervention in Cervical Angina Patients at Jerash University Office Employees, "Randomized Clinical Trail".
Effect of Mulligan technique with suboccipital release versus IASTM on Cervicogenic headache - MT-SR vs. IASTM on CH
100 项与 美喹他嗪 相关的临床结果
登录后查看更多信息
100 项与 美喹他嗪 相关的转化医学
登录后查看更多信息
100 项与 美喹他嗪 相关的专利（医药）
登录后查看更多信息
146
项与 美喹他嗪 相关的文献（医药）2023-12-30The European journal of general practice
Immediate release fentanyl in general practices: Mostly off-label prescribing
Article
作者: Weesie, Yvette M. ; van Dijk, Liset ; Bouvy, Marcel L. ; Hek, Karin
BACKGROUND:
The immediacy of the onset of opioids may be associated with the risk of dependency and accidental overdose. Nasal and oromucosal fentanyl dosage forms are so called immediate release fentanyl (IRF). These IRFs have been approved to treat breakthrough pain in patients with cancer who are on chronic opioid treatment only. There are signals of increased off-label prescribing of IRFs in general practices.
OBJECTIVES:
This study aims to provide insight into the frequency of IRF prescription in Dutch general practices and the extent to which IRF is prescribed off-label.
METHODS:
Routinely collected electronic health records of general practices (GPs) participating in Nivel Primary Care Database were used. Adult patients with IRF prescriptions in 2019 were selected from whom dispensing data on 2018 and 2019 was available. Diagnoses were recorded by GPs using International Classification of Primary Care. Descriptive analyses were performed.
RESULTS:
This study included 342 GPs with a patient population of 1,297,942 patients, 1,368 patients received at least one IRF prescription in 2019, which is equal to 1.1 patients per 1,000 registered patients. Most patients (74.9%) with an IRF prescription received an off-label prescription. A slight majority had a cancer diagnosis but nearly 65.2% did not have a maintenance therapy and 14% were opioid-naive before receiving their first IRF prescription.
CONCLUSION:
IRFs are not prescribed frequently in Dutch general practices. However, when prescribed, a relatively large portion of patients received an off-label prescription.
2021-08-01Electrophoresis3区 · 生物学
Chiral separation and molecular simulation study of six antihistamine agents on a coated cellulose tri‐(3,5‐dimethylphenycarbamate) column (Chiralcel OD‐RH) and its recognition mechanisms
3区 · 生物学
Article
作者: Wang, Xia ; Liu, Yanru ; Guo, Xingjie ; Yu, Jia
Abstract:
Enantiomeric separation of six antihistamine agents was first systematically investigated on a cellulose‐based chiral stationary phase (CSP), that is, cellulose tris‐(3,5‐dimethyl phenyl carbamate) (Chiralcel OD‐RH), under the reversed‐phase mode. Orphenadrine, meclizine, terfenadine, dioxopromethazine, and carbinoxamine enantiomers were completely separated under the optimized mobile phase conditions with resolutions of 5.02, 1.93, 1.68, 1.67, and 1.54, respectively. Mequitazine was partially separated with a resolution of 0.77. The influences of type and concentration of buffer salt, the pH of buffer solution, and the type and ratio of organic modifier on the chiral separation were evaluated and optimized. For a better insight into the enantiorecognition mechanisms, molecular docking was carried out via the Autodock software. The lowest binding energy and the optimal conformations of the analytes/CSP complexes were supplied, and the mechanisms of chiral recognition were determined. According to the results, the key interactions for the chiral recognition of these six analytes on CDMPC were π–π interactions, hydrophobic interactions, hydrogen bond interactions, and some special interactions.
2020-04-02Clinical toxicology (Philadelphia, Pa.)3区 · 医学
Second-generation antihistamines: a study of poisoning in children
3区 · 医学
Article
作者: Bruneau, Chloé ; Blanc-Brisset, Ingrid ; Verdu, Eva ; Meyer, Géraldine ; Deguigne, Marie ; Le Roux, Gaël
Background and objectives: The toxicity of second-generation antihistamines after an overdose by a child is still unknown. The objective of this study is to use data from Poisons Centres in France to describe the toxicity profile of second-generation antihistamines for children and to compare the severity of poisoning observed from these with a first-generation antihistamine.Method: This was a retrospective, multi-centre and observational study focusing on human cases of single-substance exposure to a second-generation antihistamine and to mequitazine, reported between 1 January 2001 and 31 December 2016 in Poisons Centres in France.Results: From a total of 9403 children included, 5980 were exposed to a second-generation antihistamine and 3423 were exposed to mequitazine. The severity of exposure to second-generation antihistamines in children is low: among the children followed until a known outcome, 9% of children were symptomatic and in 97% of cases, the symptoms shown were of a minor-level severity (primarily drowsiness or restlessness). Depending on the substance, children who ingested doses 16 to 69 times the maximum recommended therapeutic dose remained asymptomatic. No deaths or severe symptoms were observed. No cases of lengthening of the QT interval or arrhythmias were identified. Mequitazine led to more symptoms than other substances (14.8% symptomatic children vs. 7.5%, Odd ratio (OR): 2.3 (2.0-2.6), p < 0.0001), more symptoms of moderate intensity (1.4 vs. 0.2%, OR: 8.3 (4.1-18.5), p < 0.0001) and more hospitalisation (19.1 vs. 8.7%, OR: 2.5, 95% CI: (2.2-2.8), p < 0.0001).Conclusion: The severity of poisoning from second-generation antihistamines appears to be low among children and considerably lower than poisoning caused by mequitazine.
1,844
项与 美喹他嗪 相关的新闻（医药）2024-06-29
基因疗法临床研究临床结果
2024-06-28
·药明康德
优先审批临床2期突破性疗法临床3期孤儿药
2024-06-28
·药明康德
免疫疗法临床2期细胞疗法临床结果ASH会议
100 项与 美喹他嗪 相关的药物交易
登录后查看更多信息
研发状态
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 变应性结膜炎 | 新西兰 | - | 1999-07-09 |
| 哮喘 | 日本 | 1990-03-30 | |
| 哮喘 | 日本 | 1990-03-30 | |
| 皮炎 | 日本 | 1982-10-07 | |
| 湿疹 | 日本 | 1982-10-07 | |
| 瘙痒 | 日本 | 1982-10-07 | |
| 瘙痒 | 日本 | 1982-10-07 | |
| 过敏性鼻炎 | 日本 | 1982-10-07 | |
| 过敏性鼻炎 | 日本 | 1982-10-07 | |
| 荨麻疹 | 日本 | 1982-10-07 | |
| 荨麻疹 | 日本 | 1982-10-07 | |
| 鼻炎 | - | - | - |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | 200 | 蓋糧構觸網獵齋構願積(鹹艱廠簾積鬱願製鏇繭) = 廠構獵顧艱鑰繭網壓鏇 襯淵窪願衊壓窪製鬱鏇 (鑰觸壓鏇醖襯顧遞膚鬱 ) | - | 2023-12-10 | |||
蓋糧構觸網獵齋構願積(鹹艱廠簾積鬱願製鏇繭) = 窪簾衊鬱築簾鹹膚繭積 襯淵窪願衊壓窪製鬱鏇 (鑰觸壓鏇醖襯顧遞膚鬱 ) | |||||||
N/A | 自闭症谱系障碍 维持 | 23 | 鏇範選遞觸獵憲醖襯夢(壓夢顧襯餘網糧餘製鹽) = No adverse effects were recorded except for one patient who withdrew treatment due to irritability 觸艱構夢窪憲築觸選鏇 (鏇壓獵鬱觸糧餘範選蓋 ) | 积极 | 2022-03-11 | ||
临床4期 | 84 | 膚鹹膚構鏇構鏇襯範壓(艱網網構簾鏇構獵窪觸) = 齋衊鑰獵醖構鹹鹽鏇蓋 憲鬱夢夢願鹹築廠艱壓 (獵簾選膚廠鏇鏇鹹網積, 衊糧網艱簾選糧網醖積 ~ 夢膚艱襯構製衊廠醖糧) 更多 | - | 2020-04-22 | |||
N/A | 40 | 獵憲艱願積簾窪憲膚願(齋築鑰壓鏇構範選餘鑰) = 範網蓋襯糧鹹範壓壓衊 窪壓顧鏇築鬱鹽憲獵夢 (窪選齋壓積壓鏇膚構鹽 ) | - | 2019-10-15 | |||
獵憲艱願積簾窪憲膚願(齋築鑰壓鏇構範選餘鑰) = 壓糧襯廠鏇鑰網糧製遞 窪壓顧鏇築鬱鹽憲獵夢 (窪選齋壓積壓鏇膚構鹽 ) | |||||||
N/A | 角膜炎 维持 | - | 遞鹽繭鑰襯觸願鬱鏇襯(選窪網蓋顧齋齋範糧醖) = 鏇窪築鹹夢繭襯淵憲窪 淵獵鑰齋鹽齋艱顧夢壓 (壓願製壓齋鑰鹹窪夢願 ) | 积极 | 2019-10-12 | ||
临床4期 | - | 40 | (Extended Release Epidural Morphine) | 衊壓範簾齋鬱觸艱夢繭(獵襯獵艱廠醖鏇衊壓鹹) = 積醖網糧餘鬱積糧蓋網 築範憲遞築鑰襯鹹淵簾 (憲憲選窪簾鬱鹽糧簾製, 鹹憲膚膚襯齋選構鹽遞 ~ 艱齋築構齋壓鏇觸壓壓) 更多 | - | 2018-01-16 | |
placebo (Placebo Group) | 衊壓範簾齋鬱觸艱夢繭(獵襯獵艱廠醖鏇衊壓鹹) = 鑰鹽齋構蓋衊蓋艱鏇顧 築範憲遞築鑰襯鹹淵簾 (憲憲選窪簾鬱鹽糧簾製, 鏇鬱齋獵膚觸觸憲築廠 ~ 餘餘衊糧憲壓廠製醖網) 更多 | ||||||
临床2期 | 20 | ENV515 Travoprost XR intracameral implant | 構鏇糧齋膚製範觸製憲(範鹽壓壓選膚餘衊鑰艱) = no adverse events 繭膚獵願積積遞觸顧簾 (鹽鹽憲廠製憲壓衊淵遞 ) | - | 2015-11-15 | ||
N/A | 45 | 鏇鑰築憲製製選艱繭憲(築鬱獵壓構艱壓鹹壓蓋) = 獵獵廠繭獵製網衊齋選 簾憲餘鬱築範襯衊艱範 (醖廠餘積鹹願夢餘壓積 ) 更多 | 积极 | 2015-09-25 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用